Navigation Links
AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
Date:5/20/2013

NORTH CHICAGO, Ill., May 20, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today the initiation of a Phase 3 clinical study called SONAR (Study Of Diabetic Nephropathy with Atrasentan) to assess the effects of the investigational compound atrasentan - when added to standard of care - on progression of kidney disease in patients with stage 2 to 4 chronic kidney disease (CKD) and type 2 diabetes.  SONAR is a large, multinational, double-blind, placebo-controlled clinical study that is expected to enroll more than 4,000 patients with diabetic nephropathy.  The study will evaluate atrasentan's impact on renal outcomes, such as the onset of end-stage renal disease (ESRD), as defined by need for chronic dialysis, transplant or death due to renal failure progression.i

The initiation of the Phase 3 study follows results from Phase 2b studies, which were presented today during a late breaking clinical trials scientific session at the 2013 European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress in Istanbul, Turkey.ii

"There is a pressing need for new medications to treat nephropathy in patients with type 2 diabetes, who have a high risk to end up in dialysis," said Dick de Zeeuw , M.D., Ph.D., Professor and Chair of the Department of Clinical Pharmacology and Department of Nephrology at the University of Groningen, the Netherlands, and Co-Chair of the SONAR steering committee. "Phase 2 studies of atrasentan in this patient population have shown encouraging results, and we look forward to further evaluating this investigational treatment in the Phase 3 SONAR study."

Diabetic nephropathy, or diabetic kidney disease, is a common complication of diabetes and the leading cause of CKD
'/>"/>

SOURCE AbbVie
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. AbbVie Named to S&P 500 Dividend Aristocrat Index
2. AbbVie Issues Inaugural Full-Year Outlook for 2013
3. AbbVie to Present at Barclays Global Health Care Conference
4. Receptos Licenses Anti-Interleukin-13 Antibody from AbbVie for Phase 2 Development in Orphan Disease
5. AbbVie to Host First-Quarter Earnings Conference Call
6. AbbVie Reports First-Quarter 2013 Financial Results
7. AbbVie CF Scholarship Application Now Available for Exceptional Undergraduate and Graduate Students with Cystic Fibrosis
8. AbbVies Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration
9. AbbVie to Present at Bank of America Merrill Lynch 2013 Health Care Conference
10. AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease
11. AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Children,s National Health System has announced ... 5 p.m. EDT for its "Make Your Medical ... continued strong interest from inventors.  Two ... to the winning presentations at the Sheikh Zayed Institute ... Children,s National in October. For competition details,  click ...
(Date:9/22/2014)... 2014 Decision Resources Group finds that by the ... be worth $2 billion (U.S. dollars), increasing at a compound ... years (to 2018). This growth comes as Chile ... and 4.9 percent expected over the next three to five ... but highly competitive. The pharmaceutical market is dominated by prescription ...
(Date:9/22/2014)... DIEGO , Sept. 22, 2014  Aethlon ... targeted therapeutic devices to address infectious disease, cancer ... Defense Advanced Research Projects Agency (DARPA) has informed ... option to proceed with year four of a ... Aethlon on September 30, 2011 under DARPA,s Dialysis-Like ...
Breaking Medicine Technology:Calling all medical innovators: Submit your pediatric medical device pitch for Children's National competition by Sept. 29 2Calling all medical innovators: Submit your pediatric medical device pitch for Children's National competition by Sept. 29 3Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 2Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 3Aethlon Medical Receives Notice of DARPA Contract Renewal 2Aethlon Medical Receives Notice of DARPA Contract Renewal 3Aethlon Medical Receives Notice of DARPA Contract Renewal 4
(Date:9/22/2014)... September 22, 2014. Kessler researchers have published a ... psychoeducational wellness program in people with multiple sclerosis ... mental health, perceived stress, and pain. "Development ... individuals living with MS: Description and outcomes" was ... the International Journal of MS Care ...
(Date:9/22/2014)... 22, 2014 As concerns about ... power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ) in gynecological surgeries ... detailing the continued use of uterine morcellation by ... specifically discouraged these procedures. According to The Wall ... cancer risks associated with power morcellators are overblown, ...
(Date:9/22/2014)... Barbara Bronson Gray HealthDay ... It,s something every pregnant woman wonders: What can I do ... that taking iron supplements as prescribed may play a role ... spectrum disorder (ASD). The researchers found that mothers of ... iron supplements before and during pregnancy than those whose children ...
(Date:9/22/2014)... 22, 2014 In a continued effort ... Dodge Ram is launching an awareness campaign inspired by ... or #ffbBEC) aims to raise awareness and funds for ... an egg in the air and trying to catch ... and if a nominee does not complete the challenge ...
(Date:9/22/2014)... Researchers have developed a chip capable of ... the new system to test the effectiveness of ... system, called a tumor-microenvironment-on-chip (T-MOC) device, will allow ... and the barriers that prevent the targeted delivery ... University associate professor of mechanical engineering., Researchers are ...
Breaking Medicine News(10 mins):Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 4Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 2Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 3Health News:Blind Egg Challenge Raises Awareness for Foundation Fighting Blindness 2Health News:New chip promising for tumor-targeting research 2
... be appointed for Scotland for coordinating efforts when an epidemic ... for giving his expert advice will be paid ?50,000 annually.// ... can mutate to spread rapidly among human beings. The exact ... revealed. The person appointed will dedicate himself solely to a ...
... created a non-invasive sensor that will help treat ... a patient faces respiratory distress in the emergency ... via a mask. But for some people with ... down the body's breathing reflex. , ,Spotting ...
... the US and Canada are looking to India to ... ,"Our consortium is trying to network to provide ... Remmers, a pioneer in the study of sleep disorder ... the consortium would include Christian Guilleminault, known as the ...
... the press that the drug Dasatinib has led to reduction ... , This drug is very effective in the ... previously used drug Gleevec. ,Chronic myeloid leukemia (CML) ... stage and the blast stage.,Dasatinib was tried on all these ...
... to enroll in treatment trials for lung cancer, according to ... of CANCER, the journal of the American Cancer Society.// ... a part of the chemotherapy regimen are primarily approved after ... well as researchers have stressed the need to enroll more ...
... Robarts Research Institute have found that supplementation of GSK-3 ... produce immune cells which fights against cancer cells.// Researchers ... in the treatment of Alzheimer’s and diabetes to boost ... effects. ,Cancer chemotherapy apart from being ...
Cached Medicine News:Health News:Cheap Indian devices sought to treat sleep disorder 2Health News:Wonder drug Dasatinib gives hopes to leukemia patients 2
... of six analyzer models providing a range of ... include pH, PCO 2 , PO 2 , ... calcium, chloride, glucose, and lactate. Test results are ... saving design provides the smallest footprint of any ...
... The modular design of Sleepscan VISION ... as economical upgrade opportunities. Sleepscan VISION utilizes ... to the computer through a standard Ethernet ... in the computer, allowing the Sleepscan VISION ...
... first 192 channel simultaneous sampling EEG with ... routine EEG exam rooms as well as ... Optional analysis software for automatic spike ... sleep analysis. Quality Data Acquisition ,The ...
... purchase an XLTEK Mobee, you're getting an ambulatory ... the Mobee32 and the Mobee O2 can be ... traditional in-lab EEG monitoring, or in-lab sleep studies. ... for full 10/20 electrode placement. The Mobee O2 ...
Medicine Products: